[Modification of the adjuvans arthritis by carrageenin, compound 48/80, histamine- and serotonin antagonists, non-steroid antiphlogistics as well as protease inhibitors and their possible relations to inflammation mediators].
1. Injections of carrageenin (1,25 mg/kg i.v.) from the 1st to the 3rd day and then each 2nd or 3rd day inhibited paw swelling in adjuvant arthritis of the rat during the time of treatment. Injections from the 11th to the 15th day were ineffective. The level of plasma kininogen was slightly decreased but the total complement serum level was significantly lowered. 2,5 and 3 mg carrageenin/kg respectively were toxic after repeated injections. After a single administration the levels of plasma kininogen and of total serum complement were decreased by 50% although paw swelling was not affected. 2. Pentosane polysulfoester (25 mg/kg i.v.) did not influence paw swelling despite daily administration from the 1st to the 17th day. Heparin (10 000 IE/kg i.v.) was likewise ineffective. 3. Single or repeated injections of compound 48/80 (0,125-0,5 mg/kg i.v.; 1-5 mg/kg i.p.; 3-6 mg/kg s.c.), reserpine (0,2 mg/kg i.p.), cyproheptadine (5 mg/kg i.v.), bromolysergic acid diethylamide (2 x 2 mg/kg i.v.) or metiamide (10 mg/kg i.v.) were without effect on paw swelling. Neither did compound 48/80 effect the complement serum level. 4. Daily administration of chloropromazine (4-10 mg/kg p.o.) or of promethazine (10-15 mg/kg s.c. or p.o.) inhibited paw swelling in the first phase of adjuvant arthritis but not in the second one. 5. The soybean trypsin inhibitor (15 mg/kg i.v.) inhibited paw swelling significantly up to the 4th day, the Kunitz inhibitor (25 000 E/kg i.v.) was ineffective. 6. The content of prostaglandin E of the inflamed paws was increased threefold in both phases of arthritis. The results are discussed with regard to the putative role of mediators of inflammation (histamine, serotonin, kinins, prostaglandins, lysosomal enzymes, lymphokines, complement).
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000378:metabolism; D002351:Carrageenan / Q000627:therapeutic use*; D002746:Chlorpromazine / Q000627:therapeutic use*; D003533:Cyproheptadine / Q000627:therapeutic use; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D007249:Inflammation / Q000378:metabolism; D011458:Prostaglandins E / Q000378:metabolism; D051381:Rats; D012110:Reserpine / Q000627:therapeutic use; D012702:Serotonin Antagonists; D003189:p-Methoxy-N-methylphenethylamine / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D006634:Histamine H1 Antagonists; D011458:Prostaglandins E; D012702:Serotonin Antagonists; D003533:Cyproheptadine; D003189:p-Methoxy-N-methylphenethylamine; D012110:Reserpine; D002351:Carrageenan; D002746:Chlorpromazine
Beeinflussung der Adjuvansarthritis durch Carrageenin, Compound 48/80, Histamin- und Serotoninantagonisten, nichtsteroidale Antiphlogistika sowie Proteasenhemmstoffe und deren mögliche Beziehungen zu Entzündungsmediatoren